Research news, analysis and insights

Target of Rapamycin and developmental mTORopathies

The Bordey Lab has been focused on the mammalian Target of Rapamycin, mTOR. mTOR is a converging point in cell signaling, or in other terms an intracellular hub, that receives signals from diverse intracellular routes and extracellular ligands. Importantly, mTOR is dysregulated in many neurological disorders. These disorders referred to as mTORopathies include (but are not limited to) Tuberous Sclerosis Complex (TSC), autism, Alzheimer’s disease, and Schizophrenia. We have focused on TSC. Dr. Angélique Bordey holds the rank of Professor of Neuroscience at the Yale School of Medicine.

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Article

Using (mp) Magnetic Resonance Imaging to identify Prostate Cancer

Next Article

Do trypanosome turncoats wait before they commit?

×
You have free insight(s) remaining for this month.
Related Posts
error: Faculti Content is protected. Please check our Privacy Policy and Terms and Conditions.

Add the Faculti Web App to your Mobile or Desktop homescreen

Install
×